Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 21, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - August 21, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/21/14 - Achillion Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Aug. 21 Achillion Pharmaceuticals, New Haven, Connecticut, has been assigned a patent developed by nine co-inventors for "substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections." The co-inventors are Jason Allan Wiles, Hamden, Connecticut, Qiuping Wa
8/21/14 - Aerie Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Aug. 21 Aerie Pharmaceuticals, Research Triangle Park, North Carolina, has been assigned a patent developed by 12 co-inventors for "isoquinolinone Rho kinase inhibitors." The co-inventors are Todd Bosanac, New Milford, Connecticut, John David Ginn, New Milford, Connecticut, Eugene Richard Hickey, Ridgefield, Connecticut, Thomas M
8/21/14 - Amgen Updates on Results from Kyprolis Trial [Professional Services Close - Up]
Amgen and its subsidiary, Onyx Pharmaceuticals, reported that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival. "While it is unfortunate that the FOCUS study did not meet its primary endpoint of overall survival, we believe the results from the recent positive ASPIRE Phase 3 clinical trial will be su
8/21/14 - AstraZeneca: DoJ Closes Investigation into PLATO Clinical Trial for BRILINTA [Health & Beauty Close - Up]
AstraZeneca said that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. As one of AstraZeneca's growth platforms, we remain committed to delivering the full potential of this important medicine. " AstraZeneca said that in 2011 the US Foo
8/21/14 - Boehringer Ingelheim Pharmaceuticals Secures FDA's Support for Tiotropium Respimat for the Maintenance Treatment of COPD [Manufacturing Close - Up]
Boehringer Ingelheim Pharmaceuticals confirmed that the U.S. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee voted that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated with...
8/21/14 - Cardium's Chief Scientific Officer Authors Article in Journal of Cardiovascular Pharmacology [Professional Services Close - Up]
Taxus Cardium Pharmaceuticals Group reported the publication of a review article entitled "Identifying and Overcoming Obstacles in Angiogenic Gene Therapy for Myocardial Ischemia," authored by Gabor M. Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer, in the August issue of Journal of Cardiovascular Pharmacology. He played a leading role in
8/21/14 - Combine Solicitation - Induced Pluripotent Stem Cell Cardiomyocyte Generation
Office Address: Department of Health and Human Services; Food and Drug Administration; Office of Acquisitions and Grants Services; 5630 Fishers Lane, Room 2129 Rockville MD 20857-0001. Description: Department of Health and Human Services. Office of Acquisitions and Grants Services.
8/21/14 - Cortendo: First Patient Enrolled into NormoCort Phase 3 SONICS Trial [Professional Services Close - Up]
Cortendo reported that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., "Study Of NormoCort In Cushing's Syndrome." The enrollment of the first patient into the SONICS trial represents a significant milestone for Cortendo ", said Dr. Cortendo said that it successfully completed its European Investigator meeting supporting SO
8/21/14 - Direct Flow Medical, Inc. Receives CE Mark for 23mm Valve and for Implantation of All Sizes of Its Transcatheter Aortic Heart Valve Without Use of Contrast
Direct Flow Medical , Inc., a transcatheter heart valve innovator focused on improving patient outcomes, today announced it has received the CE Mark for a 23 mm sized valve as part of its Direct Flow Medical Transcatheter Aortic Valve System, expanding the patient population that can be treated with its technology. All Direct Flow Medical valves
8/21/14 - Double Ebola Doze En Route to Liberia - Trial Drug to Aid 30
FrontPageAfrica has learned that at least 30 Liberians infected with the deadly Ebola virus could benefit from an unknown trial Ebola drug said to be on its way to Liberia from Italy. Walter Gwenigale, in a letter dated August 18, 2014, to the Liberian Ambassador to Italy, Ambassador Mohammed Sheriff, obtained by FrontPageAfrica, reveals that the p
8/21/14 - Endo Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Aug. 21 Endo Pharmaceuticals, Malvern, Pennsylvania, has been assigned a patent developed by Harry Ahdieh, Lincoln University, Pennsylvania, for a "method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment." The patent application was filed on March
8/21/14 - European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review
Basilea Pharmaceutica Ltd. announces today that the European Medicines Agency has accepted its isavuconazole Marketing Authorization Application for review. Ronald Scott, Basilea's CEO, stated: "We are very pleased with the EMA's acceptance of our MAA for review. If approved by the EMA, isavuconazole would receive marketing authorization in all 2
8/21/14 - FDA Tentatively Approves Basaglar [Health & Beauty Close - Up]
The companies noted that Basaglar is Eli Lilly and Company and Boehringer Ingelheim's basal insulin, which is intended to provide long-lasting blood sugar control in between meals and during the night. With a tentative approval, the FDA has determined that Basaglar meets all of the regulatory requirements for approval, but it is subject to an autom
8/21/14 - Forward Pharma Elects Dr. Jan van de Winkel to Its Board [Professional Services Close - Up]
Forward Pharma said that it has appointed Jan van de Winkel, Ph.D President and CEO of Genmab, to its Board of Directors. "We are pleased to add Jan to our Board," said Florian Schonharting, Forward Pharma's Co-Founder and Chairman of the Board of Directors. In its release, Forward Pharma said that Dr. van de Winkel is a co-founder of Genmab and c
8/21/14 - Glaxo Receives US Approval For Asthma Treatment Arnuity Ellipta
Arnuity is not indicated for the relief of acute bronchospasm, Glaxo said. It was approved for 100 microgram and 200 microgram doses, and is administered daily via the Ellipta dry powder inhaler, which is also used for a range of other respiratory medicines in Glaxo's portfolio. It is the first asthma treatment from our new portfolio to have gained
8/21/14 - High Point Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Aug. 21 High Point Pharmaceuticals, High Point, North Carolina, has been assigned a patent developed by Soren Ebdrup, Roskilde, Denmark, for "N-adamantyl benzamides as inhibitors of 11- beta-hydroxysteroid dehydrogenase." The patent application was filed on Jan. 11, 2013. Written by Deviprasad Jena; edited by Jaya Anand.
8/21/14 - Huron Consulting Releases Its trialRxtm Service [Professional Services Close - Up]
Huron Consulting Group has reported the launch of its trialRxtm service, a Huron Life Sciences clinical trial data monitoring service that helps pharmaceutical, biotechnology and medical device companies understand and mitigate clinical trial disclosure risks. In its release, Huron Life Sciences said that its trialRx service is enabled by a proprie
8/21/14 - Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology
Illumina, Inc. today announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing- based oncology test system. Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners clinical trials
8/21/14 - Illumina Teams Up With AstraZeneca, Janssen And Sanofi
LONDON- Biotechnology company Illumina Inc. has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing or NGS-based oncology test system. AstraZeneca, Janssen Biotech, Inc., and Sanofi are the initial strategic partners. Illumina is working with the strategic partners to develop...
8/21/14 - Julie E. Russak, M.D., FAAD, Now Offering the New, FDA-Cleared Ultherapy Dcolletage Treatment
The Ulthera System recently received FDA- clearance to non-invasively treat the chest to improve lines and wrinkles on the dcollet. The use of FDA- cleared ultrasound technology enables physicians, for the first time, to see and then treat the deepest support layers of the skin typically addressed in cosmetic surgery without cutting or di
8/21/14 - Medivir: Interim Report, January June 2014*
Net turnover totalled SEK 564.0 million, of which SEK 500.7 million was contributed by royalties for simeprevir. Revenues from Medivir s own pharmaceutical sales totalled SEK 62.9 million, SEK 21.7 million of which derived from sales of Olysio and SEK 41.2 million from sales of other pharmaceuticals. Revenues from Medivir s own pharmaceutic
8/21/14 - NADDI: NPLEx Achieves Major Results in 2014 [Professional Services Close - Up]
The National Association of Drug Diversion Investigators- a nonprofit organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers in the prevention and investigation of drug diversion lauded the latest National Precursor Log Exchange results.
8/21/14 - Norway : Main content Photocure provides an update on Lumacan partnership [TendersInfo (India)]
Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that Photocure and Salix Pharmaceuticals have agreed to terminate the global licensing agreement for Lumacan, which is in early stage development to increase the detection rate of colorectal cancer through photodynamic..
8/21/14 - Novan Therapeutics: Nitricil Technology Shows Efficacy Against Multidrug Resistant Superbugs [Health & Beauty Close - Up]
Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, reported that the Company's Nitricil platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe. In its release, the Company said
8/21/14 - Patent Application Titled "Apparatus by Means of Which Pharmaceutical Products in the Form of Tablets, Hard Gelatin Capsules Or the like Are Retained...
Patent Application Titled "Apparatus by Means of Which Pharmaceutical Products in the Form of Tablets, Hard Gelatin Capsules Or the like Are Retained and Positioned in a Packaging Installation" Published Online. By a News Reporter-Staff News Editor at Politics& Government Week According to news reporting originating from Washington, D.C., by Vert
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement